Country Reports : France: The French Pharma Revolution
In France, it took a president's keynote speech to underscore the government's new understanding that there is more to pharmaceuticals than cost-containment
Q&A with Focus Reports team
Focus Reports discusses kep questions regarding France's pharma industry
Road Map for REMS
FDA's risk-reduction requirements could be the bridge to a bright new future for the pharma industry.
Emerging Markets Under Anti-Corruption Microscope
As they build market share, companies need a plan to limit exposure to steep fines and executive prosecutions.
Managing the Middle
Outsourcing the sales representative function can help pharmaceutical companies build on their bottom line.
Drug prices, doctor payments, and FDA regulatory decisions are candidates for expanded disclosure.
Once occupied by a single pharma leader, the roles of CEO, president, and board chairman are increasingly being separated. What's behind the trend?
Augmented Reality: The New, New Media
New strategies like augmented reality can increase patient compliance and knowledge.
Adherence: Missing the Mark
Why do patients drop drug therapy after 12 months?
Media Spend Trends
Pharma companies are starting to get back in the game with increased advertising spend in 2009. Do we have economic recovery to thank, or is there a deeper cause?
BP and Big Pharma: A Warning Sign
If there was ever a justification for endorsing a "triple bottom line" strategy for measuring Big Pharma's investment performance, it's the BP crisis.
In Defense of the Battered Sales Rep
Why pharma sales representatives are still the best marketers and how to make them better.
2 Commerce Drive Cranbury, NJ 08512